Sarepta Therapeutics, Inc. SRPT

Health CarePharmaceuticalsUnited States of America

Last close 19.23 USD on Nov 1, 2026, −13.5% year to date

Quant rating

Quant rating B Rank 181 of 565 in Health Care

Growth A 16 of 565
Valuation B 137 of 565
Quality B 153 of 565
Revisions C 317 of 565
Momentum C 380 of 565

Wall Street consensus Hold (2.80)Average target 22.05 USD +14.7%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 2.0B
Enterprise value: 2.0B
52-week range: 14.69 – 24.55
3-year range: 11.93 – 163.85
Dividend yield: –
Beta (5 years): 0.45
Shares outstanding: 106M
Next earnings: Nov 5, 2026

About the company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	2,198	1,902	1,243	933	702	–
Revenue growth	15.6%	53.0%	33.3%	32.9%	30.0%	32.4%
EPS (basic, normalized)	−7.13	2.34	−5.80	−8.03	−5.15	–
EPS growth	–	–	–	–	–	–
Gross margin	69.3%	83.2%	87.9%	85.0%	86.2%	82.3%
Net margin	−32.5%	12.4%	−43.1%	−75.4%	−59.7%	−39.7%
ROE	−53.5%	19.7%	−86.2%	−107.2%	−49.6%	−55.3%

Balance sheet, last quarter
Cash & short-term investments (mil)	788
Current ratio	4.42x
Long-term debt (mil)	848
Net debt (mil)	59.1
Total equity (mil)	1,528
Net debt / equity	0.04x
Net debt / EBITDA	−0.14x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	2,198	+15.6%	0.9x	−435	−269.0%	−4.7x	−7.13	−404.7%	−2.7x
2026	1,837	−16.4%	1.1x	434	+199.7%	4.7x	3.09	+143.3%	6.2x
2027	1,433	−22.0%	1.4x	101	−76.8%	20.1x	0.50	−83.7%	38.2x
2028	1,373	−4.2%	1.5x	121	+20.2%	16.7x	0.74	+46.7%	26.0x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,837	−0.2%	+0.1%	+6.0%	3.09	−3.3%	−17.3%	−1.6%
2027	1,433	+1.8%	+1.1%	−0.3%	0.50	+6.2%	−33.0%	−66.3%
2028	1,373	+0.6%	−4.2%	−5.2%	0.74	+3.0%	−40.3%	−41.9%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	413	363	467	658	745	611	399	443	731	401
Sales mean (mil)	378	391	409	628	683	530	339	392	456	364
Surprise	+9.4%	−7.3%	+14.1%	+4.9%	+9.0%	+15.3%	+17.9%	+13.0%	+60.3%	+10.1%
EPS reported	0.37	0.07	0.34	1.50	−4.60	1.89	−0.01	−3.93	2.88	−0.05
EPS mean	−0.07	0.01	−0.13	1.90	−0.95	0.75	−0.82	−1.23	0.99	0.26
Surprise	−595.7%	+1,198.7%	−353.7%	−20.9%	−385.8%	+151.8%	+98.8%	−219.3%	+190.4%	−119.4%

Peer comparison Pharmaceuticals

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
SRPT Sarepta Therapeutics, Inc.	2.0B	−0.14x	−32.5%	1.29x	6.2x	38.2x	4.7x	20.1x
LLY Eli Lilly and Company	1.33T	1.52x	31.7%	33.13x	40.2x	28.5x	32.7x	24.5x
ROPC Roche Holding AG	397.1B	–	20.9%	9.83x	19.7x	18.3x	13.9x	12.9x
AMGN Amgen Inc	251.9B	2.03x	21.0%	21.55x	20.2x	19.0x	13.6x	13.1x
GILD Gilead Sciences, Inc.	211.6B	−0.47x	28.9%	16.35x	−256.5x	17.1x	67.4x	13.0x
PFE Pfizer Inc.	174.0B	2.19x	12.4%	2.04x	10.3x	10.5x	9.3x	9.3x
Mean		1.03x	13.7%	14.03x	−26.6x	21.9x	23.6x	15.5x
Median		1.52x	21.0%	13.09x	15.0x	18.6x	13.8x	13.1x

Technical analysis

1M−1.0%
3M+20.7%
1Y−23.1%
3Y−82.6%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Sarepta Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	2,198	1,902	1,243	933	702	540
Cost of revenue	674	319	150	140	97.0	63.4
Gross profit	1,524	1,583	1,093	793	605	477
Selling, general & administrative expenses	492	558	482	451	283	318
Research & development	1,522	805	877	877	771	722
Depreciation/amortization	2.6	2.4	1.6	0.7	0.7	0.7
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	190	0	316	128	−87.5	−108
Other operating expenses	0	0	0	0	0	0
Operating income	−683	218	−583	−664	−362	−456
Net interest income (expense)	−23.3	4.4	13.0	−30.1	−56.0	−102
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	4.0	38.3	50.3	4.3	−0.8	5.0
Net income before taxes	−702	261	−520	−690	−419	−553
Provision for taxes	11.2	25.5	15.9	13.5	−0.2	1.1
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−713	235	−536	−703	−419	−554
Extraordinary items	–	–	–	–	–	–
Net income	−713	235	−536	−703	−419	−554
EBIT, normalized	−492	218	−268	−536	−450	−564
EBITDA, normalized	−435	266	−222	−494	−412	−537
Basic EPS, normalized	−7.13	2.34	−5.80	−8.03	−5.15	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Sarepta Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	940	1,355	1,676	1,989	2,116	1,939
Receivables	520	650	440	260	172	139
Total inventory	915	750	323	204	186	232
Prepaid expenses	41.3	33.5	30.2	30.6	30.6	37.6
Other current assets	123	285	110	74.2	99.8	138
Total current assets	2,538	3,073	2,579	2,558	2,604	2,485
Property, plant & equipment	471	489	357	245	237	282
Goodwill	–	–	–	–	–	–
Intangibles	28.9	26.9	29.6	7.6	14.2	13.6
Long-term investments	10.6	137	6.5	31.3	34.9	38.8
Note receivable	–	–	–	–	–	–
Other long-term assets	302	237	292	287	258	165
Total assets	3,350	3,963	3,265	3,128	3,148	2,985
Liabilities
Accounts payable	281	214	165	95.9	76.7	111
Payable/accrued	–	–	–	–	–	–
Accrued expenses	249	260	219	353	225	172
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	–	0	105	–	–	–
Other current liabilities	566	257	164	171	151	133
Total current liabilities	1,095	732	654	620	453	416
Long-term debt	829	1,137	1,133	1,544	1,097	992
Minority interest	–	–	–	–	–	–
Other liabilities	285	567	619	580	670	814
Total liabilities	2,209	2,435	2,405	2,743	2,220	2,223
Shareholders' equity
Preferred stock	0	0	0	0	0	–
Common stock	0	0	0	0	0	0
Additional paid-in capital	6,043	5,739	5,305	4,297	4,135	3,610
Retained earnings (accumulated deficit)	−4,877	−4,211	−4,446	−3,910	−3,207	−2,848
Treasury stock	−25.3	–	–	–	–	–
Other equity	0.3	−0.2	0.9	−1.7	0	0
Total equity	1,141	1,528	859	385	928	762
Total liabilities & shareholders' equity	3,350	3,963	3,265	3,128	3,148	2,985

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Sarepta Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−713	235	−536	−703	−419	−554
Depreciation, depletion & amortization	44.5	37.7	44.4	41.9	38.0	26.9
Deferred taxes	–	–	–	–	–	–
Non-cash items	385	238	472	376	35.8	80.6
Changes in working capital	78.0	−717	−481	−39.5	−98.2	554
Cash from operations	−205	−206	−501	−325	−443	107
Investing activities
Capital expenditures	−110	−147	−87.3	−33.3	−42.6	−85.7
Other investing cash flows	179	903	−78.5	−1,014	538	−36.0
Cash from investing	69.6	756	−166	−1,047	495	−122
Financing activities
Financing cash flow items	−19.4	0	−6.9	−0.7	−7.8	−4.8
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−149	125	132	233	569	687
Cash from financing	−168	125	125	233	562	682
Foreign exchange effects	–	–	–	–	–	–
Net change in cash	−304	675	−542	−1,140	614	668
Free cash flow	−315	−353	−588	−359	−486	21.8

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.